Infliximab and the risk of latent viruses reactivation in active Crohnʼs disease

Abstract

Our results support the safety of short-term infliximab treatment with respect to latent virus reactivation. The long-term effects of infliximab, particularly for the issue of lymphoproliferative disorders, warrants further studies with larger populations, but so far data are reassuring.